Skip to main content

Table 4 Lipid parameters

From: Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial

  Placebo Empagliflozin 10 mg Empagliflozin 25 mg Sitagliptin 100 mg
Baseline Change from baseline at week 76 Baseline Change from baseline at week 76 Baseline Change from baseline at week 76 Baseline Change from baseline at week 76
Total cholesterol (mmol/l) 5.03 ± 0.08 −0.03 ± 0.05 5.00 ± 0.08 0.10 ± 0.05 5.00 ± 0.08 0.24 ± 0.05 4.95 ± 0.07 0.05 ± 0.05
 Difference vs. placebo     0.12 ± 0.07   0.27 ± 0.07   0.08 ± 0.07
 p value     0.091   <0.001   0.272
 Difference vs. sitagliptin     0.04 ± 0.07   0.19 ± 0.07   
 p value     0.558   0.012   
HDL cholesterol (mmol/l) 1.26 ± 0.02 0.03 ± 0.01 1.24 ± 0.02 0.11 ± 0.01 1.25 ± 0.02 0.12 ± 0.01 1.26 ± 0.02 0.02 ± 0.01
 Difference vs. placebo     0.08 ± 0.02   0.09 ± 0.02   −0.01 ± 0.02
 p value     <0.001   <0.001   0.647
 Difference vs. sitagliptin     0.09 ± 0.02   0.09 ± 0.02   
 p value     <0.001   <0.001   
LDL cholesterol (mmol/l) 2.90 ± 0.06 −0.04 ± 0.04 2.86 ± 0.07 0.03 ± 0.05 2.75 ± 0.07 0.15 ± 0.04 2.74 ± 0.05 0.07 ± 0.04
 Difference vs. placebo     0.07 ± 0.06   0.19 ± 0.06   0.11 ± 0.06
 p value     0.248   0.002   0.088
 Difference vs. sitagliptin     −0.04 ± 0.06   0.09 ± 0.06   
 p value     0.581   0.174   
LDL/HDL cholesterol ratio 2.43 ± 0.07 −0.11 ± 0.04 2.40 ± 0.06 −0.12 ± 0.04 2.32 ± 0.06 −0.05 ± 0.04 2.30 ± 0.05 0.00 ± 0.04
 Difference vs. placebo     −0.01 ± 0.06   0.06 ± 0.06   0.12 ± 0.06
 p value     0.921   0.256   0.040
 Difference vs. sitagliptin     −0.12 ± 0.06   −0.05 ± 0.06   
 p value     0.033   0.358   
Triglycerides (mmol/l) 2.01 ± 0.09 −0.03 ± 0.11 2.08 ± 0.12 −0.13 ± 0.11 2.37 ± 0.20 −0.02 ± 0.11 2.20 ± 0.13 −0.07 ± 0.11
 Difference vs. placebo     −0.10 ± 0.16   0.01 ± 0.16   −0.04 ± 0.16
 p value     0.532   0.931   0.795
 Difference vs. sitagliptin     −0.06 ± 0.16   0.06 ± 0.16   
 p value     0.717   0.730   
  1. Baseline data are mean ± standard error, change from baseline data are adjusted mean ± standard error, based on ANCOVA in the full analysis set (last observation carried forward)
  2. HDL high density lipoprotein, LDL low density lipoprotein